COVI-VAC (U.S. COVID-19 vaccine)

In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants.

Data indicates that COVI-VAC is well tolerated, with no significant adverse events reported and that administration of the intranasal vaccine was immunogenic and capable of blocking nasal replication of the virus with minimal viral shedding, recorded at levels lower than those likely to result in subsequent transmission of COVID-19.

Furthermore, COVI-VAC was shown to stimulate both serum and mucosal antibody immune responses.

[5] In December 2020, Codagenix started a Phase I trial in the United Kingdom.

[2] In September 2021, Codagenix reported that the trial had shown COVI-VAC to be safe and immunogenic.